請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43839完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李啟明 | |
| dc.contributor.author | Wan-Tseng Hsu | en |
| dc.contributor.author | 徐莞曾 | zh_TW |
| dc.date.accessioned | 2021-06-15T02:30:10Z | - |
| dc.date.available | 2009-09-15 | |
| dc.date.copyright | 2009-09-15 | |
| dc.date.issued | 2009 | |
| dc.date.submitted | 2009-08-17 | |
| dc.identifier.citation | 1. Aylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report--2006. J Heart Lung Transplant 2006;25:869-79.
2. Avery RK. Cardiac-allograft vasculopathy. N Engl J Med 2003;349:829-30. 3. Kass M, Haddad H. Cardiac allograft vasculopathy: pathology, prevention and treatment. Curr Opin Cardiol 2006;21:132-7. 4. Matsumori A, Furukawa Y, Hashimoto T, et al. Increased circulating hepatocyte growth factor in the early stage of acute myocardial infarction. Biochem Biophys Res Commun 1996;221:391-5. 5. Morishita R, Aoki M, Hashiya N, et al. Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr Gene Ther 2004;4:199-206. 6. Yamaura K, Ito K, Tsukioka K, et al. Suppression of acute and chronic rejection by hepatocyte growth factor in a murine model of cardiac transplantation: induction of tolerance and prevention of cardiac allograft vasculopathy. Circulation 2004;110:1650-7. 7. van Loosdregt J, van Oosterhout MF, Bruggink AH, et al. The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. Circulation 2006;114:1599-607. 8. Tuzcu EM, Kapadia SR, Sachar R, et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2005;45:1538-42. 9. Lee CM, Wu YW, Chou NK, et al. Intravascular ultrasound evidence of angiographically silent allograft vasculopathy inversely correlates with circulating level of hepatocyte growth factor. J Heart Lung Transplant 2006;25:1456-61. 10. Konig A, Kilian E, Sohn HY, et al. Assessment and characterization of time-related differences in plaque composition by intravascular ultrasound-derived radiofrequency analysis in heart transplant recipients. J Heart Lung Transplant 2008;27:302-9. 11. Elahi MM, Khan JS, Matata BM. Deleterious effects of cardiopulmonary bypass in coronary artery surgery and scientific interpretation of off-pump's logic. Acute Card Care 2006;8:196-209. 12. Strain AJ, McGowan JA, Bucher NL. Stimulation of DNA synthesis in primary cultures of adult rat hepatocytes by rat platelet-associated substance(s). In Vitro 1982;18:108-16. 13. Michalopoulos G, Cianciulli HD, Novotny AR, Kligerman AD, Strom SC, Jirtle RL. Liver regeneration studies with rat hepatocytes in primary culture. Cancer Res 1982;42:4673-82. 14. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984;122:1450-9. 15. Russell WE, McGowan JA, Bucher NL. Partial characterization of a hepatocyte growth factor from rat platelets. J Cell Physiol 1984;119:183-92. 16. Thaler FJ, Michalopoulos GK. Hepatopoietin A: partial characterization and trypsin activation of a hepatocyte growth factor. Cancer Res 1985;45:2545-9. 17. Gohda E, Tsubouchi H, Nakayama H, et al. Human hepatocyte growth factor in plasma from patients with fulminant hepatic failure. Exp Cell Res 1986;166:139-50. 18. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-3. 19. Schwall RH, Chang LY, Godowski PJ, et al. Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2. J Cell Biol 1996;133:709-18. 20. Nakamura T, Nawa K, Ichihara A, Kaise N, Nishino T. Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett 1987;224:311-6. 21. Weidner KM, Arakaki N, Hartmann G, et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci U S A 1991;88:7001-5. 22. Shima N, Nagao M, Ogaki F, Tsuda E, Murakami A, Higashio K. Tumor cytotoxic /hepatocyte growth factor from human fibroblasts: cloning of its cDNA, purification and characterization of recombinant protein. Biochem Biophys Res Commun 1991;180:1151-8. 23. Montesano R, Matsumoto K, Nakamura T, Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991;67:901-8. 24. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4. 25. Naldini L, Vigna E, Narsimhan RP, et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 1991;6:501-4. 26. Kan M, Zhang GH, Zarnegar R, et al. Hepatocyte growth factor/hepatopoietin A stimulates the growth of rat kidney proximal tubule epithelial cells (RPTE), rat nonparenchymal liver cells, human melanoma cells, mouse keratinocytes and stimulates anchorage-independent growth of SV-40 transformed RPTE. Biochem Biophys Res Commun 1991;174:331-7. 27. Joplin R, Hishida T, Tsubouchi H, et al. Human intrahepatic biliary epithelial cells proliferate in vitro in response to human hepatocyte growth factor. J Clin Invest 1992;90:1284-9. 28. Takahashi M, Ota S, Terano A, et al. Hepatocyte growth factor induces mitogenic reaction to the rabbit gastric epithelial cells in primary culture. Biochem Biophys Res Commun 1993;191:528-34. 29. Rubin JS, Chan AM, Bottaro DP, et al. A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci U S A 1991;88:415-9. 30. Shima N, Itagaki Y, Nagao M, Yasuda H, Morinaga T, Higashio K. A fibroblast-derived tumor cytotoxic factor/F-TCF (hepatocyte growth factor/HGF) has multiple functions in vitro. Cell Biol Int Rep 1991;15:397-408. 31. Kataoka H, Gohda E, Matsunaga T, Ishii T, Hara H, Yamamoto I. Stimulation of DNA synthesis in skin fibroblasts by human hepatocyte growth factor/scatter factor. Cell Biol Int 1993;17:65-73. 32. Tajima H, Matsumoto K, Nakamura T. Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. FEBS Lett 1991;291:229-32. 33. Shiota G, Rhoads DB, Wang TC, Nakamura T, Schmidt EV. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proc Natl Acad Sci U S A 1992;89:373-7. 34. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol 1995;129:1177-80. 35. Igawa T, Matsumoto K, Kanda S, Saito Y, Nakamura T. Hepatocyte growth factor may function as a renotropic factor for regeneration in rats with acute renal injury. Am J Physiol 1993;265:F61-9. 36. Kawaida K, Matsumoto K, Shimazu H, Nakamura T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci U S A 1994;91:4357-61. 37. Miller SB, Martin DR, Kissane J, Hammerman MR. Hepatocyte growth factor accelerates recovery from acute ischemic renal injury in rats. Am J Physiol 1994;266:F129-34. 38. Yanagita K, Matsumoto K, Sekiguchi K, Ishibashi H, Niho Y, Nakamura T. Hepatocyte growth factor may act as a pulmotrophic factor on lung regeneration after acute lung injury. J Biol Chem 1993;268:21212-7. 39. Grant DS, Kleinman HK, Goldberg ID, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A 1993;90:1937-41. 40. Van Belle E, Witzenbichler B, Chen D, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998;97:381-90. 41. Nakamura Y, Morishita R, Higaki J, et al. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens 1996;14:1067-72. 42. Nakamura Y, Morishita R, Nakamura S, et al. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension 1996;28:409-13. 43. Nakamura Y, Morishita R, Higaki J, et al. Expression of local hepatocyte growth factor system in vascular tissues. Biochem Biophys Res Commun 1995;215:483-8. 44. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 1997;95:2552-8. 45. Iwata K, Sawa Y, Kitagawa-Sakakida S, et al. Gene transfection of hepatocyte growth factor attenuates the progression of cardiac remodeling in the hypertrophied heart. J Thorac Cardiovasc Surg 2005;130:719-25. 46. Ahmet I, Sawa Y, Iwata K, Matsuda H. Gene transfection of hepatocyte growth factor attenuates cardiac remodeling in the canine heart: A novel gene therapy for cardiomyopathy. J Thorac Cardiovasc Surg 2002;124:957-63. 47. Taniyama Y, Morishita R, Aoki M, et al. Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension 2002;40:47-53. 48. Miyagawa S, Sawa Y, Taketani S, et al. Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation 2002;105:2556-61. 49. Okazaki H, Matsumoto K, Nakamura T. Partial purification and characterization of 'injurin-like' factor which stimulates production of hepatocyte growth factor. Biochim Biophys Acta 1994;1220:291-8. 50. Matsumoto K, Tajima H, Hamanoue M, Kohno S, Kinoshita T, Nakamura T. Identification and characterization of 'injurin,' an inducer of expression of the gene for hepatocyte growth factor. Proc Natl Acad Sci U S A 1992;89:3800-4. 51. Nakano N, Morishita R, Moriguchi A, et al. Negative regulation of local hepatocyte growth factor expression by angiotensin II and transforming growth factor-beta in blood vessels: potential role of HGF in cardiovascular disease. Hypertension 1998;32:444-51. 52. Broten J, Michalopoulos G, Petersen B, Cruise J. Adrenergic stimulation of hepatocyte growth factor expression. Biochem Biophys Res Commun 1999;262:76-9. 53. Matsumoto K, Tajima H, Okazaki H, Nakamura T. Negative regulation of hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-beta 1 and glucocorticoids. J Biol Chem 1992;267:24917-20. 54. Matsumoto K, Tajima H, Okazaki H, Nakamura T. Heparin as an inducer of hepatocyte growth factor. J Biochem 1993;114:820-6. 55. Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem 1994;269:11216-23. 56. Lamszus K, Joseph A, Jin L, et al. Scatter factor binds to thrombospondin and other extracellular matrix components. Am J Pathol 1996;149:805-19. 57. Matsumori A, Ono K, Okada M, Miyamoto T, Sato Y, Sasayama S. Immediate increase in circulating hepatocyte growth factor/scatter factor by heparin. J Mol Cell Cardiol 1998;30:2145-9. 58. Zarnegar R. Regulation of HGF and HGFR gene expression. EXS 1995;74:33-49. 59. Grenier A, Chollet-Martin S, Crestani B, et al. Presence of a mobilizable intracellular pool of hepatocyte growth factor in human polymorphonuclear neutrophils. Blood 2002;99:2997-3004. 60. Sakon M, Kita Y, Takeda Y, et al. Measurement of hepatocyte growth factor in serum and plasma. Int J Clin Lab Res 1999;29:110-3. 61. Toi M, Taniguchi T, Ueno T, et al. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin Cancer Res 1998;4:659-64. 62. Liu KX, Kato Y, Narukawa M, et al. Importance of the liver in plasma clearance of hepatocyte growth factors in rats. Am J Physiol 1992;263:G642-9. 63. Tsubouchi H, Niitani Y, Hirono S, et al. Levels of the human hepatocyte growth factor in serum of patients with various liver diseases determined by an enzyme-linked immunosorbent assay. Hepatology 1991;13:1-5. 64. Tomiya T, Tani M, Yamada S, Hayashi S, Umeda N, Fujiwara K. Serum hepatocyte growth factor levels in hepatectomized and nonhepatectomized surgical patients. Gastroenterology 1992;103:1621-4. 65. Tomiya T, Nagoshi S, Fujiwara K. Significance of serum human hepatocyte growth factor levels in patients with hepatic failure. Hepatology 1992;15:1-4. 66. Sugimura K, Kim T, Goto T, et al. Serum hepatocyte growth factor levels in patients with chronic renal failure. Nephron 1995;70:324-8. 67. Sugimura K, Lee CC, Kim T, et al. Production of hepatocyte growth factor is increased in chronic renal failure. Nephron 1997;75:7-12. 68. Kulseng B, Borset M, Espevik T, Sundan A. Elevated hepatocyte growth factor in sera from patients with insulin-dependent diabetes mellitus. Acta Diabetol 1998;35:77-80. 69. Nakamura S, Morishita R, Moriguchi A, et al. Hepatocyte growth factor as a potential index of complication in diabetes mellitus. J Hypertens 1998;16:2019-26. 70. Nakamura S, Moriguchi A, Morishita R, et al. A novel vascular modulator, hepatocyte growth factor (HGF), as a potential index of the severity of hypertension. Biochem Biophys Res Commun 1998;242:238-43. 71. Sato T, Yoshinouchi T, Sugimoto T, et al. Prognostic value of serum hepatocyte growth factor in patients with acute coronary syndromes. Jpn Circ J 1999;63:583-8. 72. Kinoshita M, Miyamoto T, Ohashi N, Sasayama S, Matsumori A. Thrombosis increases circulatory hepatocyte growth factor by degranulation of mast cells. Circulation 2002;106:3133-8. 73. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326:310-8. 74. Woolf N, Davies MJ. Interrelationship between atherosclerosis and thrombosis. In: Fuster V, Verstrete M, eds. Thrombosis in cardiovascular disorders. Philadelphia: WB Saunders; 1992:41-77. 75. Kimura F, Miyazaki M, Suwa T, et al. Correlation between human hepatocyte growth factor and interleukin-6 concentrations after surgery. Hepatogastroenterology 1999;46:1030-5. 76. Komai H, Naito Y, Fujiwara K. Plasma hepatocyte growth factor levels after open heart surgery for congenital heart disease. J Cardiovasc Surg (Torino) 2002;43:799-802. 77. Conway K, Price P, Harding KG, Jiang WG. The molecular and clinical impact of hepatocyte growth factor, its receptor, activators, and inhibitors in wound healing. Wound Repair Regen 2006;14:2-10. 78. Schilling JA. Wound healing. Surg Clin North Am 1976;56:859-74. 79. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 2002;97:215-52. 80. Seghaye MC. The clinical implications of the systemic inflammatory reaction related to cardiac operations in children. Cardiol Young 2003;13:228-39. 81. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003;75:S715-20. 82. Raja SG, Dreyfus GD. Modulation of systemic inflammatory response after cardiac surgery. Asian Cardiovasc Thorac Ann 2005;13:382-95. 83. Sakaguchi H, Seki S, Tsubouchi H, Daikuhara Y, Niitani Y, Kobayashi K. Ultrastructural location of human hepatocyte growth factor in human liver. Hepatology 1994;19:1157-63. 84. Wolf HK, Zarnegar R, Michalopoulos GK. Localization of hepatocyte growth factor in human and rat tissues: an immunohistochemical study. Hepatology 1991;14:488-94. 85. Jiang W, Puntis MC, Nakamura T, Hallett MB. Neutrophil priming by hepatocyte growth factor, a novel cytokine. Immunology 1992;77:147-9. 86. Mine S, Tanaka Y, Suematu M, et al. Hepatocyte growth factor is a potent trigger of neutrophil adhesion through rapid activation of lymphocyte function-associated antigen-1. Lab Invest 1998;78:1395-404. 87. Adams DH, Harvath L, Bottaro DP, et al. Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells. Proc Natl Acad Sci U S A 1994;91:7144-8. 88. Beilmann M, Vande Woude GF, Dienes HP, Schirmacher P. Hepatocyte growth factor-stimulated invasiveness of monocytes. Blood 2000;95:3964-9. 89. Galimi F, Cottone E, Vigna E, et al. Hepatocyte growth factor is a regulator of monocyte-macrophage function. J Immunol 2001;166:1241-7. 90. Beilmann M, Odenthal M, Jung W, Vande Woude GF, Dienes HP, Schirmacher P. Neoexpression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes. Blood 1997;90:4450-8. 91. Haddadin A, Faraday N. Postoperative management of the cardiac surgical patient. In: Youh DD, Vricella LA, Baumartner WA, eds. The Johns Hopkins manual of cardiothoracic surgery. New York: Mc Graw Hill; 2006:397-411. 92. Yanagita K, Nagaike M, Ishibashi H, Niho Y, Matsumoto K, Nakamura T. Lung may have an endocrine function producing hepatocyte growth factor in response to injury of distal organs. Biochem Biophys Res Commun 1992;182:802-9. 93. Kono S, Nagaike M, Matsumoto K, Nakamura T. Marked induction of hepatocyte growth factor mRNA in intact kidney and spleen in response to injury of distant organs. Biochem Biophys Res Commun 1992;186:991-8. 94. Matsumoto K, Date K, Ohmichi H, Nakamura T. Hepatocyte growth factor in lung morphogenesis and tumor invasion: role as a mediator in epithelium-mesenchyme and tumor-stroma interactions. Cancer Chemother Pharmacol 1996;38 Suppl:S42-7. 95. Blanquaert F, Delany AM, Canalis E. Fibroblast growth factor-2 induces hepatocyte growth factor/scatter factor expression in osteoblasts. Endocrinology 1999;140:1069-74. 96. Matsumoto-Taniura N, Matsumoto K, Nakamura T. Prostaglandin production in mouse mammary tumour cells confers invasive growth potential by inducing hepatocyte growth factor in stromal fibroblasts. Br J Cancer 1999;81:194-202. 97. Matsumoto K, Okazaki H, Nakamura T. Novel function of prostaglandins as inducers of gene expression of HGF and putative mediators of tissue regeneration. J Biochem 1995;117:458-64. 98. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 1997;57:3305-13. 99. Matsumoto K, Okazaki H, Nakamura T. Up-regulation of hepatocyte growth factor gene expression by interleukin-1 in human skin fibroblasts. Biochem Biophys Res Commun 1992;188:235-43. 100. Gohda E, Matsunaga T, Kataoka H, Takebe T, Yamamoto I. Induction of hepatocyte growth factor in human skin fibroblasts by epidermal growth factor, platelet-derived growth factor and fibroblast growth factor. Cytokine 1994;6:633-40. 101. Jaffe R, Flugelman MY, Halon DA, Lewis BS. Ventricular remodeling: from bedside to molecule. Adv Exp Med Biol 1997;430:257-66. 102. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569-82. 103. Hein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003;107:984-91. 104. Borer JS, Truter S, Herrold EM, et al. Myocardial fibrosis in chronic aortic regurgitation: molecular and cellular responses to volume overload. Circulation 2002;105:1837-42. 105. Wang Y, Ahmad N, Wani MA, Ashraf M. Hepatocyte growth factor prevents ventricular remodeling and dysfunction in mice via Akt pathway and angiogenesis. J Mol Cell Cardiol 2004;37:1041-52. 106. Nakamura T, Matsumoto K, Mizuno S, Sawa Y, Matsuda H. Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. Am J Physiol Heart Circ Physiol 2005;288:H2131-9. 107. Ahmet I, Sawa Y, Yamaguchi T, Matsuda H. Gene transfer of hepatocyte growth factor improves angiogenesis and function of chronic ischemic myocardium in canine heart. Ann Thorac Surg 2003;75:1283-7. 108. Kosai K, Matsumoto K, Nagata S, Tsujimoto Y, Nakamura T. Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem Biophys Res Commun 1998;244:683-90. 109. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-41. 110. Hein S, Schaper J. The extracellular matrix in normal and diseased myocardium. J Nucl Cardiol 2001;8:188-96. 111. Pinto YM, Pinto-Sietsma SJ, Philipp T, et al. Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 Rat. Hypertension 2000;36:747-54. 112. Schultz Jel J, Witt SA, Glascock BJ, et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002;109:787-96. 113. El-Menyar AA, Al Suwaidi J, Holmes DR, Jr. Left main coronary artery stenosis: state-of-the-art. Curr Probl Cardiol 2007;32:103-93. 114. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000;106:1511-9. 115. Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N. Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology 2000;93:168-74. 116. Shimada Y, Yoshiyama M, Jissho S, et al. Hepatocyte growth factor production may be related to the inflammatory response in patients with acute myocardial infarction. Circ J 2002;66:253-6. 117. Sato T, Fujieda H, Murao S, Sato H, Takeuchi T, Ohtsuki Y. Sequential changes of hepatocyte growth factor in the serum and enhanced c-Met expression in the myocardium in acute myocardial infarction. Jpn Circ J 1999;63:906-8. 118. Matsumori A, Miyazaki S, Takano H, et al. Circulating hepatocyte growth factor as a marker of thrombus formation in unstable angina pectoris. Jpn Circ J 2000;64:805-7. 119. Suzuki H, Murakami M, Shoji M, et al. Hepatocyte growth factor and vascular endothelial growth factor in ischaemic heart disease. Coron Artery Dis 2003;14:301-7. 120. Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N. Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease. Heart Vessels 2000;15:105-11. 121. Sato T, Yoshinouchi T, Sakamoto T, et al. Hepatocyte growth factor(HGF): a new biochemical marker for acute myocardial infarction. Heart Vessels 1997;12:241-6. 122. Watanabe K, Fukuda H, Sueda S, Funada J, Kitakaze M, Sekiya M. Metabolism of hepatocyte growth factor in the heart in patients with coronary artery disease: implication for coronary arteriosclerosis. Cardiovasc Drugs Ther 2001;15:147-53. 123. Assey ME, Spann JF, Jr. Indications for heart valve replacement. Clin Cardiol 1990;13:81-8. 124. Flezzani P, McIntyre RW, Xuan YT, Su YF, Leslie JB, Watkins WD. Atrial natriuretic peptide plasma levels during cardiac surgery. J Cardiothorac Anesth 1988;2:274-80. 125. Katoh H, Shimada T, Inoue S, et al. Reduced high serum hepatocyte growth factor levels after successful cardioversion in patients with atrial fibrillation. Clin Exp Pharmacol Physiol 2004;31:145-51. 126. Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999;20:1799-807. 127. Fisher C, Berry C, Blue L, Morton JJ, McMurray J. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 2003;89:879-81. 128. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002;105:1760-3. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43839 | - |
| dc.description.abstract | 背景：
心臟異體移植血管病變 (cardiac allograft vasculopathy, CAV) 為心臟移植病患手術一年以後死亡之主因。已有研究指出，心臟移植病患血液循環中肝細胞生長因子 (hepatocyte growth factor，HGF) 濃度較高者，其CAV發生嚴重程度較低，但此HGF血液循環濃度升高現象是否受心臟移植手術本身所影響則未知。本試驗研究HGF於接受開心手術病患血液循環濃度的變化，作為後續應用HGF於CAV臨床治療之基礎。 方法： 受試者依據所接受之開心手術，分為使用體外循環 (cardiopulmonary bypass) 與未使用體外循環兩組，分別於開心手術前、開心手術後7天、30天、90天四個時間點，收集血液樣本；並將分離所得之血漿利用酵素連結免疫吸附分析方法 (Enzyme-linked immunosorbent assay, ELISA) 測量HGF濃度。獲得HGF濃度變化之初步結果後，再於開心手術後1天、5天、7天三個時間點收集血液樣本，分析HGF於手術後急性期之濃度變化。 結果： 肝細胞生長因子血漿濃度自手術前1296.1 ± 118.9 pg/mL，至手術後7天顯著升高至1820.2 ± 104.9 pg/mL (p < 0.05)，但於手術後30天已回至基礎值；且於手術後各個時間點，HGF濃度並未因手術中使用體外循環與否而有顯著差異。於開心手術後7天之急性期內，手術中使用體外循環者HGF濃度變化 (手術前為1569.10 ± 303.36 pg/mL；手術後第1天為4751.71 ± 971.28 pg/mL )則顯著高於未使用體外循環者(手術前為1131.16 ± 107.6 pg/mL；手術後第1天為 1970.98 ± 146.81 pg/mL，p < 0.05)。 結論： 開心手術趨使體內HGF濃度升高的影響於手術後30天已消失，故於心臟移植病患手術後一年體內HGF濃度與CAV嚴重程度的負相關性，已不受開心手術此變因的干擾。開心手術中使用體外循環增強手術後HGF濃度變化的現象，則需進一步收納相同病因的病人以釐清疾病本身的干擾。 | zh_TW |
| dc.description.abstract | Background— Cardiac allograft vasculopathy (CAV) is the leading cause of death after the first year in heart transplant recipients. An inverse correlation has been reported between circulating hepatocyte growth factor (HGF) levels and the severity of CAV. Before further application, the dynamically regulated production of HGF triggered by surgical insults after open heart surgery should be clarified.
Methods and Results— We investigated the serial change in plasma HGF levels in 50 patients undergoing open heart surgery. The patients were divided into two groups, depending on the use of cardiopulmonary bypass (CPB): CPB group and off-pump coronary artery bypass (OPCAB) group. For the initial 34 patients, the measurement time points were 7 (POD7), 30 (POD30), and 90 days postoperatively (POD90). The plasma HGF levels significantly increased from baseline (1296.1 ± 118.9 pg/mL) to 1820.2 ± 104.9 pg/mL (p < 0.05) on POD7, returning to baseline on POD30, and did not have any significant difference between groups at each time point. For the latter 16 patients, the measurement time points were 1(POD1), 5 (POD5), and 7 days postoperatively (POD7) in the postoperative acute phase. The response changes of plasma HGF levels were significantly higher in patients operated upon procedures requiring CPB. Conclusions— High plasma HGF levels after open heart surgery may indicate the occurrence or necessity for tissue protection and regeneration after acute systemic insults with temporal effect fading out on the 30th postoperative day and thereafter. Thus the inverse correlation between circulating HGF levels and the severity of CAV detected by intravascular ultrasound at least 1 year after heart transplantation is not influenced by the duration post-operation. Further study is required to clarify the difference in response changes in plasma HGF levels during postoperative acute phase is made by CPB use or patient’s underlying disease indicated for surgical intervention. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T02:30:10Z (GMT). No. of bitstreams: 1 ntu-98-R95451004-1.pdf: 756124 bytes, checksum: b70bca88424d72a4162e94680710d174 (MD5) Previous issue date: 2009 | en |
| dc.description.tableofcontents | Approval sheet i
Acknowledgments ii Chinese abstract iii Abstract v Contents vii List of Figures x List of Tables xiii Chapter 1 Introduction 1 1.1 Background 1 1.2 Statement of the Problem 2 1.3 Hypothesis 3 1.4 Aims 3 Chapter 2 Literature Review 5 2.1 Introduction to HGF 5 2.1.1 Discovery, structure, biological and physiological properties 5 2.1.2 Cardiovascular Application 6 2.2 Factors Regulating HGF Production 7 2.3 HGF Levels in Normal and Pathophysiological Situations 10 2.3.1 Measurement hepatocyte growth factor in serum and plasma 10 2.3.2 Alteration during aging of serum HGF levels in normal condition 10 2.3.3 HGF Levels in various disease and pathophysiological situation 11 2.3.3.1 Liver disease 11 2.3.3.2 Chronic renal failure 12 2.4 Changes of HGF after Non-cardiac and Cardiac Surgery 16 2.4.1 Serum HGF levels after non-cardiac surgery 16 2.4.2 Plasma HGF levels after open heart surgery for congenital heart disease 17 Chapter 3 Methodology 19 3.1 Patients 19 3.2 Study Protocol 20 3.3 Hepatocyte Growth Factor Level Determination 21 3.4 Statistical Analysis 30 Chapter 4 Results 33 4.1 Changes in Plasma HGF Levels in the Postoperative Chronic Phase 33 4.2 Changes in Plasma HGF Levels in the Postoperative Acute Phase 41 4.3 Factors Predicting the Baseline Plasma HGF Levels 46 Chapter 5 Discussion 48 5.1 Physiological Significance of Increase in Circulating HGF after Open Heart Surgery 48 5.2 Implication of HGF in the Pathogenesis of Cardiovascular Disease 52 5.3 Limitation 56 5.4 Suggestion for Further Work 58 Conclusions 59 References 60 | |
| dc.language.iso | en | |
| dc.subject | 體外循環 | zh_TW |
| dc.subject | 肝細胞生長因子 | zh_TW |
| dc.subject | 開心手術 | zh_TW |
| dc.subject | cardiopulmonary bypass | en |
| dc.subject | hepatocyte growth factor | en |
| dc.subject | open heart surgery | en |
| dc.title | 接受開心手術病患體內肝細胞生長因子的濃度變化 | zh_TW |
| dc.title | Serial Changes of Circulating Hepatocyte Growth Factor in Patients Undergoing Open Heart Surgery | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 97-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 許榮彬,林琬琬 | |
| dc.subject.keyword | 肝細胞生長因子,開心手術,體外循環, | zh_TW |
| dc.subject.keyword | hepatocyte growth factor,open heart surgery,cardiopulmonary bypass, | en |
| dc.relation.page | 79 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2009-08-17 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
| 顯示於系所單位： | 臨床藥學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-98-1.pdf 未授權公開取用 | 738.4 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。